Immunological effects of amivantamab in EGFR or MET-expressing non-small cell lung cancer - PubMed

8 hours ago

Amivantamab, a bispecific antibody targeting EGFR and MET, shows clinical benefits in EGFR-mutant NSCLC through dual blockade, but its direct immunological effects on tumor-infiltrating lymphocytes (TILs) in human specimens were not previously evaluated.
Analysis of 40 NSCLC patient samples revealed that EGFR mutations and high EGFR protein expression were associated with reduced infiltration of CD8+ T-cells and dendritic cells (DCs).
Ex vivo experiments with TILs demonstrated that amivantamab significantly activated CD8+ T-cells, increased programmed cell death-1 expression, enhanced cytokine production, and promoted DC maturation, particularly in tumors with high EGFR or MET protein expression rather than just EGFR mutations.
This study provides the first direct evidence from ex vivo assays that amivantamab can activate immune responses in human NSCLC specimens, suggesting EGFR and MET expression as potential biomarkers for these immunological effects.

Hasty Briefsbeta